Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKRINOL vs AKLIEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
AKLIEF (trifarotene) is a selective retinoic acid receptor (RAR) gamma agonist. It modulates gene expression by binding to RAR-gamma, leading to normalization of follicular keratinization, reduced comedogenesis, and anti-inflammatory effects.
Allergic rhinitis,Nasal congestion
FDA-approved for the topical treatment of acne vulgaris in patients 9 years of age and older
Adults: 100 mg orally twice daily.
Apply a thin layer to affected areas once daily in the evening, avoiding eyes, lips, and mucous membranes.
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless Cr Cl <30 m L/min).
Terminal elimination half-life: ~29 hours after topical application; supports once-daily dosing.
Not available; components may be metabolized via hepatic CYP enzymes.
Trifarotene is metabolized primarily via CYP2D6 and to a lesser extent via CYP3A4. It undergoes extensive first-pass metabolism with low systemic exposure after topical application.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
Fecal: ~70% as unchanged drug; Renal: <1% as metabolites.
99.5% (primarily to albumin; also to α1-acid glycoprotein).
>99% bound to plasma proteins (primarily albumin and lipoproteins).
0.10-0.17 L/kg (low, indicating limited extravascular distribution; primarily in central compartment).
Not determined for topical route; systemic absorption minimal with Vd not clinically relevant.
Oral: 3-5% (extensive first-pass metabolism); IV: 100%.
Topical: ~1% systemic absorption; oral: not applicable.
GFR 30-59 m L/min: 50 mg daily; GFR <30 m L/min: 50 mg every other day.
No dose adjustment required in renal impairment. Not studied in severe renal impairment.
Child-Pugh A: 100 mg twice daily; Child-Pugh B: 50 mg twice daily; Child-Pugh C: 50 mg daily.
No dose adjustment required in mild to moderate hepatic impairment (Child-Pugh A, B). Not studied in severe hepatic impairment (Child-Pugh C).
Children (1-12 years): 2 mg/kg orally twice daily, max 100 mg/dose.
Approved for acne vulgaris in patients aged 12 years and older: apply a thin layer to affected areas once daily in the evening.
Adults >65 years: initiate at 50 mg twice daily, titrate to 100 mg twice daily as tolerated.
No specific dose adjustment required; clinical studies did not include sufficient geriatric patients to determine differential response.
None
None.
Use with caution in patients with hypertension,Avoid in patients with severe coronary artery disease
Local skin reactions (erythema, scaling, dryness, stinging/burning) may occur; reduce frequency or discontinue if severe.,Avoid excessive exposure to sunlight or UV light; use sunscreens and protective clothing.,Avoid contact with eyes, mouth, angles of the nose, and mucous membranes.,Pregnancy: Limited data; no known risk of major malformations based on animal studies, but use only if clearly needed.
Hypersensitivity to any component,Severe hypertension,Concomitant use with MAO inhibitors
Hypersensitivity to trifarotene or any component of the formulation
No known food interactions with topical naftifine. No dietary restrictions required.
No significant food interactions reported. Avoid excessive alcohol consumption as it may exacerbate skin dryness and irritation. No specific dietary restrictions.
FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, renal dysfunction, necrotizing enterocolitis, periventricular hemorrhage, and pulmonary hypertension.
Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show embryofetal toxicity at high doses. Risk cannot be ruled out. Second and third trimesters: Limited data; avoid unless benefit outweighs risk.
Contraindicated during breastfeeding. M/P ratio not determined due to contraindication. Excreted into breast milk; potential for serious adverse effects in infant.
No data on excretion in human milk; M/P ratio unknown. Caution advised due to potential for serious adverse reactions in nursing infants.
No established safe dose. Generally contraindicated during pregnancy. If used, lowest effective dose and shortest duration. Avoid after 20 weeks gestation.
No specific dose adjustments recommended; pharmacokinetic changes in pregnancy unknown. Use lowest effective dose if necessary.
AKRINOL is a topical antifungal (naftifine) that inhibits squalene epoxidase, effective against dermatophytes. Apply once daily for 2-4 weeks. Avoid occlusive dressings. Monitor for local irritation or allergic contact dermatitis.
AKLIEF (trifarotene) is a fourth-generation retinoid selective for RAR-γ receptors, minimizing irritation compared to tretinoin. Use pea-sized amount for entire face; avoid excessive application. Initiate every other night to improve tolerability. Concomitant use of benzoyl peroxide or salicylic acid may increase dryness; advise non-comedogenic moisturizers. Contraindicated in pregnancy (Category X); rule out pregnancy before starting.
Apply a thin layer to the affected area once daily, usually for 2 to 4 weeks.,Wash hands before and after application unless treating the hands.,Do not cover the treated area with bandages or wraps unless directed.,Avoid contact with eyes, nose, mouth, or broken skin. If contact occurs, rinse with water.,Notify your doctor if condition worsens, does not improve within 4 weeks, or if severe irritation or allergic reaction develops.
Apply a thin layer once daily at night to clean, dry skin.,Avoid sun exposure and use broad-spectrum SPF 30+ sunscreen daily.,May cause initial redness, peeling, and dryness; use moisturizer.,Do not use if pregnant or planning pregnancy; use effective contraception.,Do not apply to cuts, abrasions, or eczematous skin.,Avoid waxing or laser hair removal during treatment.,Therapeutic effect may take 8-12 weeks.,Keep out of reach of children and away from eyes, mouth, and mucous membranes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKRINOL vs AKLIEF, answered by our medical review team.
AKRINOL is a Topical Retinoid that works by Not available; likely a combination product with antihistaminic and sympathomimetic actions.. AKLIEF is a Topical Retinoid that works by AKLIEF (trifarotene) is a selective retinoic acid receptor (RAR) gamma agonist. It modulates gene expression by binding to RAR-gamma, leading to normalization of follicular keratinization, reduced comedogenesis, and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKRINOL and AKLIEF depend on the specific clinical indication. These are both Topical Retinoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKRINOL is: Adults: 100 mg orally twice daily.. The standard adult dose of AKLIEF is: Apply a thin layer to affected areas once daily in the evening, avoiding eyes, lips, and mucous membranes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKRINOL and AKLIEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKRINOL is classified as Category C. FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, re. AKLIEF is classified as Category C. Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show embryofetal toxicity at high doses. Risk cannot be ruled out. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.